REGENXBIO Inc. (RGNX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026. REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapies using its proprietary NAV Technology Platform. The company's lead programs include ABBV-RGX-314 (sura-vec) for retinal diseases, RGX-202 for Duchenne muscular dystrophy, and RGX-121/RGX-111 for Mucopolysaccharidosis (MPS) disorders. The company operates as a single segment and relies heavily on licensing revenue and collaboration agreements.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $6,393 | $89,012 |
| Net Income (Loss) | $(90,051) | $6,083 |
| Operating Loss | $(83,362) | $12,127 (Income) |
| Net Cash Used in Operating Activities | $(76,186) | $33,629 (Provided) |
| Cash, Cash Equivalents & Marketable Securities | $150,491 | $240,910 |
| Total Royalty Monetization Liabilities | $177,330 | $187,017 |
| Accumulated Deficit | $(1,216,078) | $(926,066) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $82.6 million (93%) compared to Q1 2025. This was primarily due to the absence of a $70.0 million upfront license payment from Nippon Shinyaku recognized in Q1 2025. Additionally, Zolgensma royalties decreased by $12.2 million due to the expiration of licensed patents in the U.S. in mid-January 2026.
- Cost of Revenue Spike: Cost of license and royalty revenues increased by $7.6 million to $11.1 million. This was driven by a $10.0 million non-recurring settlement payment to GlaxoSmithKline (GSK) to resolve a dispute over sublicense fees.
- Operating Expenses: Research and Development (R&D) expenses increased by $4.3 million to $57.3 million, driven by clinical trial costs for RGX-202 and increased personnel. General and Administrative (G&A) expenses rose slightly by $1.0 million.
- Liquidity Position: Cash and marketable securities decreased by approximately $90 million from the prior year period, reflecting the burn rate and lack of large upfront payments in the current quarter.
Guidance, Outlook, and Risks
- Going Concern Warning: Management states that conditions raise substantial doubt about the company's ability to continue as a going concern within 12 months. Current cash resources ($150.5 million) are estimated to fund operations only into early 2027.
- Regulatory Challenges:
- RGX-121 (MPS II): Received a Complete Response Letter (CRL) from the FDA in February 2026. The FDA cited uncertainties regarding study eligibility and surrogate endpoints. A partial clinical hold was lifted in April 2026. The company has filed a Formal Dispute Resolution Request.
- RGX-111 (MPS I): Placed on partial clinical hold in January 2026 following the identification of a CNS tumor in a patient, linked to AAV vector integration at the PLAG1 gene site.
- Positive Developments:
- RGX-202 (Duchenne): Announced positive topline results from the pivotal Phase III trial in May 2026, achieving the primary endpoint with high statistical significance. The company plans to pursue accelerated approval and a potential commercial launch in 2027.
- Sura-vec (AbbVie): Enrollment for pivotal trials in wet AMD is complete. The NAAVIGATE trial for diabetic retinopathy is expected to dose the first patient in Q2 2026, triggering a $100 million milestone payment.
- Legal Proceedings: Two securities-related lawsuits were filed in early 2026 alleging misrepresentation regarding RGX-111 safety. The company intends to vigorously defend these claims and has not recorded a liability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $150.5 million cash balance against the projected burn rate and the timeline for the next potential financing or milestone payment.
- RGX-121 Path Forward: Monitor the outcome of the Formal Dispute Resolution Request with the FDA and the feasibility of the proposed new study designs to address the CRL.
- RGX-111 Safety Data: Review the full analysis of the tumor case and the FDA's stance on the clinical hold to assess the viability of the RGX-111 program.
- AbbVie Milestone Timing: Confirm the timeline for the first patient dose in the NAAVIGATE trial to validate the expected $100 million revenue recognition in Q2 2026.
- Royalty Monetization Obligations: Assess the impact of the $177.3 million royalty monetization liabilities on future cash flows, particularly as Zolgensma royalties decline due to patent expirations.